Myogen's darusentan meets Phase IIb endpoint

MYOG was up $8.13 (60%) to $21.67 on 25.7 million shares on Thursday after announcing that darusentan met the primary endpoint of reducing sitting systolic blood pressure in the Phase IIb DAR-201 tria...